In a short-term perspective, the company has interesting fundamentals.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Sales forecast by analysts have been recently revised upwards.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
Stock prices approach a strong long-term resistance in weekly data at USD 160.4.
Technically, the stock approaches a strong medium-term resistance at USD 155.95.
The company is in debt and has limited leeway for investment
The company's enterprise value to sales, at 5.25 times its current sales, is high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the past year, analysts have significantly revised downwards their profit estimates.
Sector Medical Equipment, Supplies & Distribution - NEC